Kalaris Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KLRS and other ETFs, options, and stocks.About KLRS
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases.
KLRS Key Statistics
Stock Snapshot
Kalaris Therapeutics(KLRS) stock is priced at $9.12, giving the company a market capitalization of 170.57M. It carries a P/E multiple of -1.23.
On 2025-12-22, Kalaris Therapeutics(KLRS) stock moved within a range of $9.00 to $10.50. With shares now at $9.12, the stock is trading +1.3% above its intraday low and -13.1% below the session's peak.
Trading volume for Kalaris Therapeutics(KLRS) stock has reached 251.54K, versus its average volume of 262.35K.
The stock's 52-week range extends from a low of $2.14 to a high of $12.90.
The stock's 52-week range extends from a low of $2.14 to a high of $12.90.
KLRS News
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Kalaris Therapeutics (KLRS) announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell...
Kalaris Therapeutics (KLRS) announced initial data from its Phase 1a single ascending dose trial of TH103, a fully humanized, recombinant fusion protein that ac...